文献速递肺栓塞与肺血管病

低危肺栓塞早期出院后的生存率与生活质量

Survival and quality of life after early discharge in low-risk pulmonary embolism.
PubMed 文献 · Eur Respir J · 2021-02-04

HoT-PE单臂管理试验纳入576例低危肺栓塞患者,评估早期出院后利伐沙班门诊治疗。3个月复发率为0.5%(单侧95%CI上限1.3%),1年死亡率为2.4%。疾病特异性与通用生活质量及治疗满意度在3个月内均显著改善。

要点

  • 低危肺栓塞早期出院后口服利伐沙班,3个月复发率0.5%(单侧95%CI上限1.3%)。
  • 1年死亡率为2.4%,支持早期出院策略的安全性。
  • PEmb-QoL、EQ-5D-5L及ACTS负担评分在3个月内均显著改善。

核心结论

  • 结果进一步支持对选定低危肺栓塞患者实施早期出院和门诊口服抗凝治疗。

研究设计与样本

  • HoT-PE为多国、单臂管理试验,评估早期出院后利伐沙班门诊治疗,本分析纳入全部576例患者。

主要发现

  • 3个月复发(主要疗效终点)发生于3例(0.5%,单侧95%CI上限1.3%)。
  • 1年死亡率为2.4%。
  • PEmb-QoL均值从3周时28.9±20.6%降至3个月时19.9±15.4%,平均改善-9.1%(p<0.0001),各维度一致改善。
  • EQ-5D-5L从3周时0.89±0.12改善至3个月时0.91±0.12(p<0.0001);ACTS负担评分从40.5±6.6分改善至42.5±5.9分(p<0.0001)。
  • 女性及心肺疾病与较差的疾病特异性和通用生活质量相关;年龄较大与通用生活质量更快恶化相关。

关键数值与推荐

  • 主要疗效终点3个月复发率0.5%(单侧95%CI上限1.3%)。
  • 1年死亡率为2.4%。
  • PEmb-QoL平均改善-9.1%(p<0.0001);EQ-5D-5L改善至0.91±0.12(p<0.0001);ACTS负担评分改善至42.5±5.9分(p<0.0001)。

临床怎么用

  • 对选定低危肺栓塞患者可考虑早期出院并给予利伐沙班门诊口服抗凝治疗。
  • 需关注女性、心肺疾病患者及高龄患者的生活质量,可能需针对性策略进一步改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Early discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life outcomes. METHODS: The multinational Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE) single-arm management trial investigated early discharge followed by ambulatory treatment with rivaroxaban. The study was stopped for efficacy after the positive results of the predefined interim analysis at 50% of the planned population. The present analysis includes the entire trial population (576 patients). In addition to 3-month recurrence (primary outcome) and 1-year overall mortality, we analysed self-reported disease-specific (Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire) and generic (five-level five-dimension EuroQoL (EQ-5D-5L) scale) quality of life as well as treatment satisfaction (Anti-Clot Treatment Scale (ACTS)) after pulmonary embolism. RESULTS: The primary efficacy outcome occurred in three (0.5%, one-sided upper 95% CI 1.3%) patients. The 1-year mortality was 2.4%. The mean±sd PEmb-QoL decreased from 28.9±20.6% at 3 weeks to 19.9±15.4% at 3 months, a mean change (improvement) of -9.1% (p<0.0001). Improvement was consistent across all PEmb-QoL dimensions. The EQ-5D-5L was 0.89±0.12 at 3 weeks after enrolment and improved to 0.91±0.12 at 3 months (p<0.0001). Female sex and cardiopulmonary disease were associated with poorer disease-specific and generic quality of life; older age was associated with faster worsening of generic quality of life. The ACTS burden score improved from 40.5±6.6 points at 3 weeks to 42.5±5.9 points at 3 months (p<0.0001). CONCLUSIONS: Our results further support early discharge and ambulatory oral anticoagulation for selected patients with low-risk pulmonary embolism. Targeted strategies may be necessary to further improve quality of life in specific patient subgroups.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Barco S, Schmidtmann I, Ageno W, et al. Survival and quality of life after early discharge in low-risk pulmonary embolism. Eur Respir J. 2021. PMID: 32859673. doi:10.1183/13993003.02368-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。